Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
Dear Readers,Welcome to the latest issue of Microb
AstraZeneca in June chose Emergent to assist make 300 million doses of its possible COVID-19 vaccine vowed to the USA.
AstraZeneca has signed manufacturing deals internationally to meet its goal of earning 2 billion gallons of this vaccine, for example with just two Bill Gates-backed ventures and a $1.2 billion deal with the US authorities.
The company’s vaccine, which is co-developed from the University of Oxford, is among the very first to move into mid-stage trials. There are no approved vaccines or treatments for COVID-19, the highly infectious respiratory illness brought on by the novel coronavirus.
The latest contract follows a $87 million deal in June where Emergent signed an agreement to become the growth partner for AstraZeneca’s COVID-19 vaccine candidate.
Activities under the agreement will likely be at Emergent’s Baltimore Bayview centre, the company said, which is a designated centre by the US Department of Health and Human Services for rapid manufacturing of large quantities of vaccines and treatments.
